#Canada #Vancouver #Zero Candida #FemTech #VVC Treatment

Zero Candida Technologies: Financial and Business Updates

Zero Candida Technologies, Inc. (TSXV: ZCT) is making significant strides in the Femtech sector, focusing on innovative solutions for women's gynecological health. In its recent report concerning the financial results for the three and six months ending on June 30, 2025, the company demonstrated progress in both its operational and financial metrics.

Financial Highlights

During the second quarter of 2025, Zero Candida's operating expenses amounted to CAD 0.31 million, primarily driven by research and development efforts and corporate costs. This figure marks a slight decrease from the CAD 0.35 million incurred in the same period of 2024. For the first half of 2025, the operating expenses totaled CAD 0.67 million, a drop from CAD 0.91 million in 2024, signaling effective cost management as the company progresses toward product readiness.

The general and administrative expenses also reflected a downward trend, with costs recorded at CAD 0.11 million for Q2 2025, down from CAD 0.14 million in the previous year. The total net loss for the second quarter stood at CAD 0.28 million, compared to CAD 0.21 million in Q2 2024. For the six-month period ending June 30, 2025, the net loss was CAD 0.59 million, less than the CAD 0.77 million reported the year before.

As of June 30, 2025, the company reported cash and cash equivalents of CAD 0.46 million, an improvement from CAD 0.24 million at the end of 2024. The assets on hand totaled CAD 2.77 million, with a working capital of CAD 1.53 million. Management believes these resources will support the ongoing development of their innovative products for at least the next year.

Business Progress and Strategic Goals

Zero Candida Technologies remains focused on the development of its flagship product, the ZC–01 device. This innovative SMART medical solution harnesses AI and therapeutic blue light targeting Vulvo-Vaginal Candidiasis (VVC), a condition that affects around 75% of women globally. The company is advancing towards its regulatory goals with an anticipated De Novo FDA pathway and is preparing for both B2B and B2C strategies to enhance market reach.

Eli Ben-Haroosh, Chairman and CEO, emphasized the importance of Q2 as a pivotal point for device development, utilization of regulatory frameworks, and building partnerships with hospitals and pharmaceutical companies. The ongoing conversations with key stakeholders reinforce the need and potential of their technology to revolutionize women's health care.

As the global regulatory landscape becomes increasingly stringent regarding chemical-based health products, Zero Candida aims to offer safer, drug-free alternatives to patients. Their innovative technology addresses the growing concerns regarding antifungal resistance and highlights the necessity for accessible non-drug treatment options.

Future Outlook

Looking ahead, Zero Candida Technologies has outlined a series of upcoming milestones:

• - Final preclinical results are expected by Q2 2026.
• - Laboratory validation studies will follow in Q3 2026, leading up to pilot clinical trials in Israel by the end of 2026.
• - Targeted clinical trials in the U.S. are set for Q3 2027.

The VVC treatment market is projected to exceed USD 2 billion by 2030, positioning Zero Candida for substantial growth as it aims to democratize access to critical gynecological care.

Conclusion

In conclusion, Zero Candida Technologies is positioning itself as a frontrunner in the Femtech arena with its innovative, AI-driven solutions to improve women's health. The strategic focus on effective resource management and regulatory compliance, combined with ongoing discussions with major health stakeholders, places the company on a promising trajectory for sustainable growth and impact in the women's health sector.

To learn more about Zero Candida Technologies and their groundbreaking initiatives, visit www.zero-candida.com.